This episode, titled 'Availability, Patient Preference, and Linvoseltamab: What Pharmacists Need to Know About the Evolving Bispecific Landscape,' features oncology pharmacists discussing the following critical questions:
In 'Patient Selection and Line-of-Therapy Navigation: Practical Insights for a Complex Myeloma Treatment Landscape,' our panel of experts delve into the following critical questions:
In this episode, 'The Long-Term Infection Risk: How Pharmacists Are Approaching Prophylaxis and Monitoring in Bispecific Myeloma Care,' the oncology pharmacists explore the following questions:
In this episode, 'From Treatment to Prevention: How Pharmacists Are Refining CRS Management for Bispecific Antibody Therapy,' the oncology pharmacists explore the following questions:
In 'Getting CRS Right: Clinical Presentation, Appropriate Response, and Building a Well-Educated Care Team,' our panel of experts delve into the following critical questions:
In this episode, 'Reducing Hospitalization Without Compromising Safety: Step-Up Dosing Criteria and Best Practices in Myeloma,' the oncology pharmacists explore the following questions:
In 'Pharmacists at the Center: Managing REMS Education, Compliance, and Collaboration Across Care Settings,' our panel of experts delve into the following critical question:
This episode, titled 'Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs,' features oncology pharmacists discussing the following critical question:
In 'Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management,' our panel of experts delve into the following critical question:
In this episode, 'When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs,' the oncology pharmacists explore the following question:
This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:
In 'When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma,' our panel of experts delve into the following critical question:
In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question:
1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?
Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?
